Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances

Alkermes plc anticipates record proprietary product sales exceeding $1 billion for 2025, driven by strong Q2 performance and advancements in its orexin pipeline. CEO Richard F. Pops highlighted sustained profitability, no debt, and over $1 billion in cash. Q2 revenues reached $390.7 million, with proprietary product net sales of $307.2 million, reflecting 14% year-over-year growth. The company is on track to meet or exceed its financial guidance, with expectations for continued growth in proprietary product sales. Analysts expressed cautious optimism regarding safety and regulatory pathways for alixorexton, while management remained confident in its data and product efficacy.